Related Experiment Video
Updated: Aug 20, 2026

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Newer antistaphylococcal agents
1Division of Infectious Diseases, Children's Hospital San Diego, San Diego, California 92123, USA. jbradley@chsd.org
Purpose Of Review:
As antibiotic resistance in staphylococci continues to evolve, the ability to treat infections in children with confidence using first-generation cephalosporins, penicillins, and macrolides is decreasing. Knowledge of the local trends in resistance is important in making decisions of empiric antibiotic therapy. The antibiotic resistance pattern for the child's pathogen should be assessed whenever possible, to allow the practitioner to properly judge the risks and benefits of alternative antibiotic agents, should they be required for definitive therapy.
Recent Findings:
Options for therapy of most methicillin-resistant and macrolide-resistant community-acquired strains of Staphylococcus aureus include vancomycin, linezolid, and, in communities with a high proportion of susceptible strains, clindamycin. Daptomycin, a lipopeptide antibiotic with activity against virtually all strains of S. aureus, was recently approved by the United States Food and Drug Administration for adults. Second-generation glycopeptide antibiotics similar to vancomycin are in clinical trials in adults, including dalbavancin and oritavancin. Several new compounds, including cephalosporins active against methicillin-resistant S. aureus, are in preclinical development as well.
Summary:
The recent worldwide emergence and rapid spread of community-acquired methicillin-resistant S. aureus has prompted a change in the approach to therapy of staphylococcal infections in both the outpatient clinic and the hospital. Newer agents active against methicillin-resistant S. aureus such as linezolid have been recently approved for children and other agents recently approved for adults are under investigation in children. Older agents for which relatively few data from prospective, controlled, comparative studies exist in the treatment of staphylococcal infections may also offer effective and less costly options for therapy.
Insights
Antibiotic resistance in staphylococci is rising, impacting pediatric treatments. Assessing local resistance patterns is crucial for effective empiric and definitive antibiotic therapy decisions in children.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Resistance
- Staphylococcal Infections
Background:
- Increasing antibiotic resistance in staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA), challenges traditional pediatric treatments with first-generation cephalosporins, penicillins, and macrolides.
- Local resistance trends are critical for guiding empiric antibiotic therapy decisions in pediatric staphylococcal infections.
- Assessing pathogen-specific resistance patterns allows for informed selection of alternative antibiotic agents for definitive therapy.
Purpose of the Study:
- To review the evolving landscape of antibiotic resistance in staphylococci affecting children.
- To highlight the importance of understanding local resistance patterns for effective treatment strategies.
- To discuss current and emerging therapeutic options for staphylococcal infections in pediatric populations.
Main Methods:
- Review of current literature on antibiotic resistance trends in staphylococci.
- Analysis of therapeutic options for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in children.
- Evaluation of newly approved and investigational agents for staphylococcal infections.
Main Results:
- Treatment of MRSA and macrolide-resistant Staphylococcus aureus in children may involve vancomycin, linezolid, or clindamycin (if susceptible).
- Daptomycin is approved for adults, with second-generation glycopeptides (dalbavancin, oritavancin) in adult clinical trials.
- New cephalosporins active against MRSA are in preclinical development.
Conclusions:
- The rise of CA-MRSA necessitates a revised approach to treating staphylococcal infections in pediatric care.
- Newer agents like linezolid are approved for children, while adult-approved medications are under investigation for pediatric use.
- Older, less costly antibiotic agents may still offer effective treatment options for staphylococcal infections, though data from prospective studies are limited.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Staphylococcal Skin Infections
Hand hygiene
Hand washing...
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Antimicrobial Effectiveness
